J8650 HCPCS code: Nabilone, oral, 1 mg
J8650 is the HCPCS Level II code for nabilone, oral, 1 mg. CMS terminated J8650 on 2025-12-31; do not bill it for later dates of service. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2007-01-01 |
| Last action effective | 2026-01-01 |
| Terminated | 2025-12-31 |
What changed for J8650
- 2007-01-01: J8650 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J8650?
J8650 is the HCPCS Level II code for nabilone, oral, 1 mg. Short descriptor: "Nabilone oral".
Does Medicare cover J8650?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J86 codes
- J8600 — Melphalan; oral, 2 mg
- J8610 — Methotrexate; oral, 2.5 mg
- J8611 — Methotrexate (jylamvo), oral, 2.5 mg
- J8612 — Methotrexate (xatmep), oral, 2.5 mg
- J8655 — Netupitant 300 mg and palonosetron 0.5 mg, oral
- J8670 — Rolapitant, oral, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J8650
- Watch J8650 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J8650
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.